Metropolis Healthcare has launched a new pneumonia panel across its labs in India. Unlike conventional detection methods which are rather slow, Metropolis’s pneumonia panel is equipped to deliver accurate pathogen identification in about two hours, says the company.
By providing quick tests for pneumonia, the panel enables physicians to provide appropriate early antimicrobial therapy.
Lower respiratory tract infections are caused by a variety of microorganisms such as bacterias, viruses, and fungus. Pneumonia patients often have to undergo over-treatment with antibiotics as it is difficult to easily identify the underlying pathogen causing their symptoms.
Pneumonia panel can help physicians provide appropriate antimicrobial therapy by testing for respiratory pathogens in sputum, endotracheal aspirates, bronchioloalveolar lavage (BAL), and mini-BAL specimens.
The panel is designed to identify particularly 11 Gram-negative, 4 Gram-positive and 3 atypical bacteria; 7 antibiotic resistance genetic markers, and 9 viruses that cause pneumonia and other lower respiratory tract infections.
It also provides semi-quantitative results for 15 bacteria out of the total 18, which may help determine whether an organism is a colonizer or a pathogen.
Antimicrobial therapy may be modified based on the results of the panel. As it identifies various genetic markers associated with drug resistance, it also greatly helps to modify treatment plans at the earliest and provide clinicians with vital information to deal with difficult to treat drug-resistant bacteria.